We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Detecto

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Feb 2023 - 18 Feb 2023

mHealth Device Identifies Heart Problems in Cancer Survivors

By HospiMedica International staff writers
Posted on 05 Jul 2018
Print article
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
Image: The Vivio app measuring pulse on an iPhone (Photo courtesy of Niema Pahlevan/ USC).
A novel handheld platform can accurately detect cardiac dysfunction in childhood cancer survivors, according to a new study.

The Vivio device, developed at the California Institute of Technology (Caltech; Pasadena, USA), the University of Southern California (USC; Los Angeles, USA), and other institutions, is a handheld device that collects pulse waves and phonocardiogram data from the carotid artery and sends it wirelessly to an app on a compatible device, such as a smartphone or tablet. Using a specialized algorithm, left ventricular ejection fraction (LVEF) is calculated; an LVEF measure of less than 50% may indicate signs of abnormal heart function.

To test the accuracy of the device, researchers at the Childhood Cancer Survivorship Clinic (CCSC) at City of Hope (Duarte, CA, USA) conducted a cross-sectional study that compared LVEF using the Vivio wireless device, two-dimensional (2D) echocardiography, and gold-standard cardiac magnetic resonance (CMR) imaging in childhood cancer survivors exposed to anthracycline, who risk potential cardiac dysfunction from the exposure, which can often develop at a time when they are least engaged in long-term survivorship care.

In all, 191 consecutive cancer survivors participated in the study, with a median anthracycline dose of 225 mg/m². The researchers found that echocardiography overestimated mean LVEF by 4.9% compared with CMR, but no difference was seen between mean LVEF derived from the Vivio and CMR. Also, when compared with CMR, the detection of cardiac dysfunction via echocardiography was poor, but Vivio-based measurements had considerably better sensitivity. The study was published on June 21, 2018, in Clinical Cancer Research.

“The pediatric oncology community is becoming increasingly aware that there are new issues faced by many cancer survivors that may not manifest themselves until decades after their cancer treatment is done,” said lead author pediatric hematologist/oncologist Saro Armenian, DO, MPH, director of the CCSC. “One of these issues is a higher burden of cardiovascular disease, which can result from exposure to anthracyclines as part of their cancer treatment.”

“One possible implementation of Vivio could be for preliminary screening. If the patient's heart function is below a specific threshold as measured by Vivio, that patient could schedule an in-depth evaluation,” concluded Dr. Armenian. “Vivio could keep these survivors engaged, and help to reduce the burden of inconvenient tests for individuals with a normal heart function as determined by the device. It could also pave the way for a mobile health-based care management program for childhood cancer survivors.”

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart with each contraction, and is usually expressed as a percentage. A normal LVEF ranges from 55-70%. An LVEF of less than 40% may confirm a diagnosis of heart failure. An LVEF of less than 35% increases the risk of an arrhythmia that can cause sudden cardiac arrest or death, and an ICD may be recommended for these patients.

Related Links:
California Institute of Technology
University of Southern California
City of Hope

Gold Supplier
SBRT Phantom with Removable Spine
E2E SBRT Phantom with Removable Spine Model 036S-CVXX-xx
New
Mechanical Ventilator
NKV-550 Series
New
Surgical Table
ARCUS 601
New
Endoscopy Display
EndoVue Plus 24”

Print article

Channels

AI

view channel
Image: A novel research study moves the needle on predicting coronary artery disease (Photo courtesy of Pexels)

AI-Enabled ECG Analysis Predicts Heart Attack Risk Nearly as well as CT Scans

Increased coronary artery calcium is a marker of coronary artery disease that can lead to a heart attack. Traditionally, CT scans are used to diagnose buildup of coronary artery calcium, although CT scanners... Read more

Surgical Techniques

view channel
Image: Gut microbiota helps healing in colorectal cancer surgery (Photo courtesy of CRCHUM)

Modifying Intestinal Flora Before Surgery Reduces Postoperative Complications in Colorectal Cancer Patients

Up to 30% of all patients undergoing colorectal surgery suffer from serious complications due to poor healing of their intestinal barrier. Anastomotic complications cause inflammation, serious infection... Read more

Health IT

view channel
Image: Using digital data can improve health outcomes (Photo courtesy of Unsplash)

Electronic Health Records May Be Key to Improving Patient Care, Study Finds

When a patient gets transferred from a hospital to a nearby specialist or rehabilitation facility, it is often difficult for personnel at the new facility to access the patient’s electronic health records... Read more

Point of Care

view channel
Image: Steripath improves the diagnostic accuracy and timeliness of sepsis test results (Photo courtesy of Magnolia)

All-in-One Device Reduces False-Positive Diagnostic Test Results for Bloodstream Infections

Blood cultures are considered the gold standard diagnostic test for the detection of blood stream infections, such as sepsis. However, positive blood culture results can be frequently wrong, and about... Read more

Business

view channel
Image: The global patient positioning systems market is projected to reach USD 1.7 billion by 2027 (Photo courtesy of Pexels)

Global Patient Positioning Systems Market Driven by Increasing Chronic Diseases

The global patient positioning systems market is projected to grow at a CAGR of 4% from USD 1.4 billion in 2022 to USD 1.7 billion by 2027, driven by increasing technological advancements in medical devices,... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.